Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 19/20 | 0.63 |
| ▸ | CDC7 | O00311 | 19/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 18/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 18/20 | 0.63 |
| ▸ | HIPK2 | Q9H2X6 | 18/20 | 0.63 |
| ▸ | CLK2 | P49760 | 17/20 | 0.63 |
| ▸ | CDK7 | P50613 | 17/20 | 0.63 |
| ▸ | PRKX | P51817 | 17/20 | 0.63 |
| ▸ | PIM1 | P11309 | 17/20 | 0.63 |
| ▸ | STK17A | Q9UEE5 | 17/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.63 |
| ▸ | CDK2 | P24941 | 17/20 | 0.63 |
| ▸ | FLT3 | P36888 | 17/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 16/20 | 0.63 |
| ▸ | PAK4 | O96013 | 16/20 | 0.63 |
| ▸ | GSK3B | P49841 | 16/20 | 0.63 |
| ▸ | CDK9 | P50750 | 16/20 | 0.63 |
| ▸ | PKN2 | Q16513 | 16/20 | 0.63 |
| ▸ | MINK1 | Q8N4C8 | 16/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 16/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049713 | 0.90 | PRKACA (0.68) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL994464 | 0.90 | CDC7 (0.61) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1046262 | 0.89 | CDC7 (0.65) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1044498 | 0.86 | CDC7 (0.64) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL15190059 | 0.84 | PIM1 (0.58) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1045920 | 0.84 | CDC7 (0.66) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1044798 | 0.83 | CDC7 (0.65) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1043917 | 0.81 | CDC7 (0.72) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL992965 | 0.79 | CDC7 (0.81) | PRKACACDC7DAPK3CDK5HIPK2 | |
| SCHEMBL1044957 | 0.79 | CDC7 (0.69) | PRKACACDC7DAPK3CDK5HIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | claimed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | PRKACA 78/4885CDC7 1/4885DAPK3 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.